AA
XENE icon

ALPS Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

ALPS Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.89M Buy
97,610
+29,887
+44% +$1.66M 0.03% 253
2026
Q1 		$3.94M Buy
67,723
+4,421
+7% +$204K 0.02% 290
2025
Q4 		$2.84M Buy
63,302
+26,002
+70% +$1.09M 0.02% 334
2025
Q3 		$1.5M Sell
37,300
-4,080
-10% -$144K 0.01% 433
2025
Q2 		$1.3M Sell
41,380
-13,952
-25% -$455K 0.01% 443
2025
Q1 		$1.86M Sell
55,332
-6,316
-10% -$240K 0.01% 359
2024
Q4 		$2.42M Buy
61,648
+4,659
+8% +$193K 0.02% 319
2024
Q3 		$2.24M Sell
56,989
-1,864
-3% -$75.2K 0.02% 337
2024
Q2 		$2.29M Buy
58,853
+5,653
+11% +$226K 0.02% 317
2024
Q1 		$2.29M Buy
53,200
+2,420
+5% +$111K 0.02% 329
2023
Q4 		$2.34M Buy
50,780
+3,431
+7% +$121K 0.02% 313
2023
Q3 		$1.62M Buy
47,349
+626
+1% +$23.4K 0.01% 356
2023
Q2 		$1.8M Buy
46,723
+5,195
+13% +$207K 0.02% 331
2023
Q1 		$1.49M Sell
41,528
-843
-2% -$31.1K 0.01% 364
2022
Q4 		$1.67M Buy
42,371
+8,412
+25% +$306K 0.01% 336
2022
Q3 		$1.23M Buy
33,959
+2,461
+8% +$88.5K 0.01% 397
2022
Q2 		$958K Buy
+31,498
New +$953K 0.01% 486
2022
Q1 		– Sell
-59,702
Closed -$1.86M – 999
2021
Q4 		$1.86M Buy
59,702
+9,287
+18% +$278K 0.02% 296
2021
Q3 		$770K Sell
50,415
-3,544
-7% -$61.6K 0.01% 416
2021
Q2 		$1M Sell
53,959
-9,372
-15% -$173K 0.01% 400
2021
Q1 		$1.13M Buy
63,331
+77
+0.1% +$1.3K 0.01% 384
2020
Q4 		$973K Buy
63,254
+18,630
+42% +$218K 0.01% 392
2020
Q3 		$494K Sell
44,624
-3,080
-6% -$36.2K 0.01% 447
2020
Q2 		$598K Buy
+47,704
New +$607K 0.01% 425
2019
Q4 		– Sell
-51,356
Closed -$463K – 863
2019
Q3 		$463K Sell
51,356
-2,532
-5% -$23.9K ﹤0.01% 506
2019
Q2 		$531K Sell
53,888
-7,076
-12% -$67.7K ﹤0.01% 516
2019
Q1 		$619K Buy
60,964
+3,168
+5% +$26.9K ﹤0.01% 450
2018
Q4 		$365K Buy
+57,796
New +$514K ﹤0.01% 674

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ALPS Advisors's XENE Position: Q2 2026 in Review

ALPS Advisors increased its Xenon Pharmaceuticals (XENE) stake by 44% in Q2 2026, buying an estimated $1.66M and bringing the position to 97,610 shares worth $5.89M. The position accounts for 0.03% of the portfolio, ranked #253.

ALPS Advisors first reported a position in XENE in Q4 2018 and has held it in 28 quarters since. 96 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • ALPS Advisors held 97,610 shares of Xenon Pharmaceuticals worth $5.89M as of Q2 2026.
  • ALPS Advisors bought 29,887 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.66M.
  • Xenon Pharmaceuticals made up 0.03% of ALPS Advisors's portfolio in Q2 2026, its #253 holding.
  • ALPS Advisors first reported a position in Xenon Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
  • 96 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.